CN-680000-ME216-A6.pdf

AHCA CONTRACT NO. MED216

AMENDMENT NO. 6

AHCA Contract No. MED216, Amendment No. 6, Page 1 of 3

THIS CONTRACT, entered into between the STATE OF FLORIDA, AGENCY FOR HEALTH CARE ADMINISTRATION, hereinafter referred to as the "Agency" and FLORIDA MEDICAL SCHOOLS QUALITY NETWORK, INC., hereinafter referred to as the "Vendor," is hereby amended as follows:

1. Standard Contract, Section II., THE AGENCY HEREBY AGREES, Sub-Section A., Contract Amount, the first sentence is hereby amended to now read as follows:

To pay for contracted services according to the conditions of Attachment I, Scope of Services, in an amount not to exceed $1,097,965.00 (an increase of $250,000.00), subject to the availability of funds.

2. Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1., Projects to be Completed by the Vendor, is hereby amended to include Sub-Item d., Project 4: Maternal and Infant Mortality Report, as follows:

d. Project 4: Maternal and Infant Mortality Report

The purpose of this project is to conduct a review and produce a report to identify the Medicaid enrollees with maternal and infant mortality as described in the 2024 General Appropriations Act, Specific Appropriation 194. The Agency shall submit the report to the Governor, the President of the Senate, the Speaker of the House of Representatives, and the Florida Department of Health Office of Minority Health and Health Equity by December 1, 2024. The Agency shall also publish the report on its website in a manner that is easily accessible by the public.

The Vendor shall conduct the following activities, at a minimum, in meeting the requirements of this contract:

i. Identify the number of enrollees who have died in childbirth and near birth, as defined and agreed upon by the Agency, and provide detailed information as directed by the Agency including, but not limited to:

1) Age and population demographics

2) Health care utilization patterns

3) All prenatal and post-natal services provided

4) Recipient geographic location

ii. Conduct research utilizing maternal and fetal mortality data from other entities as identified and approved by the Agency.

iii. Conduct data analyses for a specific time period as directed and approved by the Agency.

iv. Prepare and submit a written report in consultation with and as directed by the Agency.

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF https://www.flsenate.gov/Session/Bill/2024/5001/BillText/er/HTML https://www.flsenate.gov/Session/Bill/2024/5001/BillText/er/HTML

AHCA Contract No. MED216, Amendment No. 6, Page 2 of 3

3. Attachment I, Scope of Services, Exhibit A-2, Revised Deliverables, Financial Consequences, and Performance Standards is hereby deleted in its entirety and replaced with Exhibit A-3, Revised Deliverables, Financial Consequences, and Performance Standards attached hereto and made a part of this Contract. All references in this Contract to Exhibit A-2 shall hereinafter also refer to Exhibit A-3.

All provisions not in conflict with this Amendment are still in effect and are to be performed at the level specified in this Contract.

This Amendment and all its attachments are hereby made a part of this Contract.

This Amendment cannot be executed unless all previous Amendments to this Contract have been fully executed.

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Amendment No. 6, Page 3 of 3

IN WITNESS WHEREOF, the Parties hereto have caused this fifteen (14) page Amendment to be executed by their officials thereunto duly authorized. This Amendment is not valid until signed and dated by both Parties.

FLORIDA MEDICAL SCHOOLS QUALITY

NETWORK, INC

STATE OF FLORIDA, AGENCY FOR

HEALTH CARE ADMINISTRATION

SIGNED

BY:

SIGNED

BY:

NAME: NAME:

TITLE: TITLE:

DATE: DATE:

List of Attachments included as part of this Amendment:

Specify Type Number Description Attachment I Exhibit A-3 Revised Deliverables, Financial

Consequences, and Performance Standards (11 pages)

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199

10/7/2024 | 14:28 EDT

Dr. Charles Lockwood

EVP USF Health, Dean, Morsani College of Medicine

Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

Jason Weida

Secretary

10/14/2024

ATTACHMENT I

EXHIBIT A-3

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES, AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-3, Page 1 of 11

1.

DELIVERABLE 1

D01: Donor Milk Bank Timeline

SUPPORTING DOCUMENTATION

The Vendor shall submit a timeline that provides a description of the activities and due dates that shall be completed for the Study on the Use of Donor Human Milk as a supplement to newborn care for infants born prematurely and hospitalized within the NICU in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

July 30, 2021 or within five (5) days of execution of this Contract, whichever is sooner

(COMPLETED)

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

2.

DELIVERABLE 2

D02: Donor Human Milk Banks

SUPPORTING DOCUMENTATION

The Vendor shall submit a list of donor human milk banks and companies supplying donor-derived human milk to infants in Florida in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 1, 2021 (COMPLETED)

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 2 of 11

3.

DELIVERABLE 3

D03: Donor Human Milk Safety

SUPPORTING DOCUMENTATION

The Vendor shall submit an itemized list and description of the safety considerations in utilizing human milk for newborns in the NICU and the adulterants and contaminants that can be transmitted via human milk in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 17, 2021 (COMPLETED)

AMOUNT

$115,988.33

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 3 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

4.

DELIVERABLE 4

D04: Donor Human Milk Data

SUPPORTING DOCUMENTATION

The Vendor shall submit data showing the use by Florida hospitals of donor human milk made available via donor human milk banks and the related health outcomes and achieved cost-savings for both Medicaid and commercial payors regarding newborn care within a NICU in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 24, 2021 (COMPLETED)

AMOUNT

$115,988.33

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 3 of 11

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 4 in the time and manner specified in

5.

DELIVERABLE 5

D05: Donor Human Milk Data Recommendations

SUPPORTING DOCUMENTATION

The Vendor shall submit recommendations of best practices which must address, at a minimum: the operation of a donor human milk tissue bank that facilitates the donation, processing and distribution of donor human milk tissue and donor human milk tissue derivatives; procedures for donation and distribution of donor human milk tissue and donor human milk tissue derivatives; and testing of donor human milk tissue and donor human milk tissue derivatives before donation, processing, and distribution to ensure the absence of adulterants and other contaminants, in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 24, 2021 (COMPLETED)

AMOUNT

$115,988.34

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 5 in the time and manner specified in

6.

DELIVERABLE 6

Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.b.

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 4 of 11

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

November 1, 2022, or as otherwise approved by the Agency. (COMPLETED)

AMOUNT

$118,222.20

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 1 in the time and manner specified in

7.

DELIVERABLE 7

Final Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

December 1, 2022, or as otherwise approved by the Agency. (COMPLETED)

AMOUNT

$78,814.80

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 2 in the time and manner specified in

8.

DELIVERABLE 8

Criteria for Florida Centers of Excellence for Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 5 of 11

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

2/10/2023 (COMPLETED)

AMOUNT

$9,755.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 8 in the time and manner specified in

9.

DELIVERABLE 9

Provider Education on Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/28/2023 (COMPLETED)

AMOUNT

$10,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 9 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

10. DELIVERABLE 10

Preferred Drug List for Treating Patients with Sickle Cell Disease

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 6 of 11

11.

DELIVERABLE 11

Performance Measures for Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/21/2023 (COMPLETED)

AMOUNT

$8,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 11 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

3/31/2023 (COMPLETED)

AMOUNT

$20,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1..

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 10 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 7 of 11

13.

DELIVERABLE 13

Biennial Sickle Cell Disease (SCD) Report Outline (Calendar Years 2022 and 2023)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Report outline for the biennial report due beginning November 1, 2024.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

February 1, 2024 (COMPLETED)

AMOUNT

$20,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.c.

12.

DELIVERABLE 12

External Funding Opportunities for a Florida Consortium of Centers of Excellence in Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

5/19/2023 (COMPLETED)

AMOUNT

$5,208.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 12 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 8 of 11

FINANCIAL CONSEQUENCES

Failure to complete and submit the deliverables that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

14.

DELIVERABLE 14

Draft Sickle Cell Disease (SCD) Study Report (Calendar Year 2022)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Draft Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.c, and shall include, at a minimum, the following components: the purpose of the report; an executive summary;

consultations; background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

May 30, 2024 (COMPLETED)

AMOUNT

$200,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1. c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the deliverables that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 9 of 11

15.

DELIVERABLE 15

Final Draft Sickle Cell Disease (SCD) Study Report (Calendar Year 2022)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.c, and shall include, at a minimum, the following components: the purpose of the report, an executive summary;

consultations; background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

June 30, 2024 (COMPLETED)

AMOUNT

$30,000

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the deliverables that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 10 of 11

16.

DELIVERABLE 16

Draft Maternal and Infant Mortality Report

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a draft Maternal and Infant Mortality Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.d.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

October 1, 2024

AMOUNT

$225,000

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.d.

17.

DELIVERABLE 17

Final Sickle Cell Disease (SCD) Study Report (Calendar Years 2022 and 2023)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a revised Sickle Cell Disease Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.c, and shall include, at minimum, the data analysis for calendar years (CYs) 2022 and 2023 and all of the Agency’s feedback and requested edits.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

October 31, 2024

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.c.

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF

AHCA Contract No. MED216, Exhibit A-3, Page 11 of 11

18.

DELIVERABLE 18

Final Maternal and Infant Mortality Report

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Maternal and Infant Mortality Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.d. and shall include all of the Agency’s feedback and requested edits.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

November 1, 2024

AMOUNT

$25,000

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.d.

Docusign Envelope ID: 4B28EDA1-389D-4C39-AB4F-97B5C3CC215CDocusign Envelope ID: 09F35C81-4C74-4E37-87C2-07A24A478199Docusign Envelope ID: 32C53801-D8DF-4353-AD09-E7DB16B023FF